Dominic Piscitelli sold $1.1M of ORIC
Chief Financial Officer at Oric Pharmaceuticals, Inc.. 77,000 shares at an average of $13.69, traded Aug 26, 2026, filed Aug 28, 2026.
Score components
- +22RoleCFO
- +25Trade size$1.1M at market
- +20Share of holdings soldSold 52% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001695028-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | MOption exercise Common Stock10b5-1 | +52,000 | $4.36 | $227k | 121,828 | Aug 28, 2026 |
| Aug 26, 2026 | MOption exercise Common Stock10b5-1 | +25,000 | $6.00 | $150k | 146,828 | Aug 28, 2026 |
| Aug 26, 2026 | SOpen-market sale Common Stock10b5-1 | -77,000 | $13.69 | $1.1M | 69,828 | Aug 28, 2026 |
| Aug 26, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -52,000 | $0.00 | $0 | 92,500 | Aug 28, 2026 |
| Aug 26, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 120,000 | Aug 28, 2026 |
Related signals
Other insiders at Oric Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 2Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $87k 6,700 shares | -16% | |
| 12Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $181k 13,400 shares | -16% | |
| 0Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $8,103 600 shares | -1% | |
| 1Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $157k 13,100 shares | -29% | |
| 0Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $3,600 300 shares | -0% | |
| 18Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $703k 52,000 shares | -43% | |
| 9Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $80k 6,700 shares | -15% | |
| 39Weak | Oric Pharmaceuticals, Inc. | Jacob Chacko PRESIDENT AND CEO | $302k 33,374 shares | -5% | |
| 30Weak | Oric Pharmaceuticals, Inc. | Pratik S Multani Chief Medical Officer | $97k 10,720 shares | -14% | |
| 37Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $97k 10,720 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.